
BioCryst Pharmaceuticals Investor Relations Material
Latest events

Q1 2025
BioCryst Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from BioCryst Pharmaceuticals Inc
Access all reports
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company offers peramivir, an intravenous neuraminidase inhibitor, which completed Phase III clinical trial for the treatment of acute uncomplicated influenza in hospitalized adult and pediatric patients in Japan; BCX4161, an oral purine nucleoside phosphorylase (PNP) inhibitor for the treatment of hereditary angioedema; galidesivir, a broad spectrum viral RNA polymerase inhibitor that is under pre-clinical development against various high priority viruses associated with biodefense threat; and BCX9250 that is under pre-clinical development for the treatment of gout.
Key slides for BioCryst Pharmaceuticals Inc


Q2 2024
BioCryst Pharmaceuticals Inc


Q4 2024
BioCryst Pharmaceuticals Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
BCRX
Country
🇺🇸 United States